160 related articles for article (PubMed ID: 35801373)
61. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Farley J; Brady WE; Vathipadiekal V; Lankes HA; Coleman R; Morgan MA; Mannel R; Yamada SD; Mutch D; Rodgers WH; Birrer M; Gershenson DM
Lancet Oncol; 2013 Feb; 14(2):134-40. PubMed ID: 23261356
[TBL] [Abstract][Full Text] [Related]
62. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
[TBL] [Abstract][Full Text] [Related]
63. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
[TBL] [Abstract][Full Text] [Related]
64. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract][Full Text] [Related]
65. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
[TBL] [Abstract][Full Text] [Related]
66. Low-Grade Serous Carcinoma of the Ovary.
Grisham RN
Oncology (Williston Park); 2016 Jul; 30(7):650-2. PubMed ID: 27422112
[No Abstract] [Full Text] [Related]
67. Not All Peritoneal Implants Are Created Equal.
Varghese A; Shih IM
Gynecol Oncol; 2020 Jan; 156(1):1-2. PubMed ID: 31954499
[No Abstract] [Full Text] [Related]
68. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
69. Ovarian serous borderline tumors with noninvasive and invasive peritoneal implants: A case report each.
Srinivasamurthy BC; Kulandai Velu AR; Krishnan N; Patil AS
J Cancer Res Ther; 2015; 11(3):646. PubMed ID: 26458602
[TBL] [Abstract][Full Text] [Related]
70. KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
Nakamura K; Nakayama K; Ishibashi T; Ishikawa N; Ishikawa M; Katagiri H; Minamoto T; Sato E; Sanuki K; Yamashita H; Iida K; Sultana R; Kyo S
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128903
[TBL] [Abstract][Full Text] [Related]
71. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer.
Zeppernick F; Meinhold-Heerlein I
Arch Gynecol Obstet; 2014 Nov; 290(5):839-42. PubMed ID: 25082067
[TBL] [Abstract][Full Text] [Related]
72. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
73. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.
Ayhan A; Kurman RJ; Yemelyanova A; Vang R; Logani S; Seidman JD; Shih IeM
Am J Surg Pathol; 2009 Aug; 33(8):1220-4. PubMed ID: 19461510
[TBL] [Abstract][Full Text] [Related]
74. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
[TBL] [Abstract][Full Text] [Related]
75. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract][Full Text] [Related]
76. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
Singer G; Oldt R; Cohen Y; Wang BG; Sidransky D; Kurman RJ; Shih IeM
J Natl Cancer Inst; 2003 Mar; 95(6):484-6. PubMed ID: 12644542
[TBL] [Abstract][Full Text] [Related]
77. Mutation analysis of papillary tubal hyperplasia associated with ovarian atypical proliferative serous tumor and low-grade serous carcinoma.
Huang WC; Tsai CC; Wei MC; Kuo KT
Am J Obstet Gynecol; 2013 Aug; 209(2):e6-8. PubMed ID: 23711666
[TBL] [Abstract][Full Text] [Related]
78. New therapeutic opportunities for women with low-grade serous ovarian cancer.
Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
[TBL] [Abstract][Full Text] [Related]
79. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract][Full Text] [Related]
80. BRAF
Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
